Skip to main content
Clinical Trials/NCT00902382
NCT00902382
Completed
Not Applicable

Registry of Pregnancies Conceived Following Exposure to Ovulation Stimulation Medications

Yale University13 sites in 1 country264 target enrollmentMay 2009
ConditionsInfertility

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Infertility
Sponsor
Yale University
Enrollment
264
Locations
13
Primary Endpoint
The relative risk of structural anomalies
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

To identify adverse effects of ovulation drugs on pregnancy, including pregnancy loss, fetal teratology and dysmorphology, and infant development up to age 3.

Detailed Description

This will be an observational cohort trial of the pregnancy of women who conceive in RMN trials, and of their resulting infants through the first 3 years of life. Study specific procedures will include a patient completed log of prescribed and over the counter medications taken during a normal pregnancy, a review of their pregnancy, delivery, and neonatal records, an exam of the infant within 60 days of birth by a dysmorphologist, and yearly review of infant medical records, growth charts, and a yearly parent administered developmental questionnaire (Ages and Stages) for the first three years of the infant's life.

Registry
clinicaltrials.gov
Start Date
May 2009
End Date
June 27, 2014
Last Updated
8 years ago
Study Type
Observational
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Heping Zhang

Principal Investigator

Yale University

Eligibility Criteria

Inclusion Criteria

  • Positive serum hCG within the context of a RMN trial;
  • History of infertility meeting female subject entry criteria for a RMN trial;
  • Informed consent.

Exclusion Criteria

  • Unable to comply with the demands of the trial.

Outcomes

Primary Outcomes

The relative risk of structural anomalies

Time Frame: 2009 - 2016

The relative risk of cognitive differences

Time Frame: 2009 - 2016

The relative risk of perceived differences of neuro-developmental milestones

Time Frame: 2009 - 2016

The relative risks of genetic abnormalities identified at birth and within the first 60 days of life

Time Frame: 2009 - 2016

Secondary Outcomes

  • Rates of infant growth related to use of letrozole for stimulation of ovulation compared to other treatment modalities for ovulation stimulation, including compared to women who conceive spontaneously.(2009 - 2016)
  • The rate of pregnancy complications, including pregnancy loss(2009 - 2016)
  • Rates of neonatal and infant medical disorders(2009 - 2016)

Study Sites (13)

Loading locations...

Similar Trials